Dougados M, Boumier P, Amor B
Br Med J (Clin Res Ed). 1986 Oct 11;293(6552):911-4. doi: 10.1136/bmj.293.6552.911.
Sulphasalazine has been reported to be effective in ankylosing spondylitis with peripheral arthritis, but its efficacy in spondylitis is unknown. Thus 60 patients with active ankylosing spondylitis without peripheral arthritis or gastrointestinal symptoms were randomly allocated to one of two therapeutic groups. One group received 2 g sulphasalazine daily for six months and the other a placebo. Thirteen patients (six given placebo and seven given sulphasalazine) dropped out of the trial and were considered to be treatment failures. After six months' follow up efficacy was rated as good or very good by 15 of the 30 patients given sulphasalazine and by only six of the 30 given placebo (p less than 0.02). Furthermore, in the patients given sulphasalazine the daily consumption of non-steroidal anti-inflammatory drugs, functional index, and plasma IgG concentrations had fallen significantly. These data suggest that sulphasalazine may be a safe and effective treatment for spondylitis in ankylosing spondylitis.
据报道，柳氮磺胺吡啶对伴有外周关节炎的强直性脊柱炎有效，但其对脊柱炎的疗效尚不清楚。因此，将60例无外周关节炎或胃肠道症状的活动性强直性脊柱炎患者随机分为两个治疗组。一组患者每日服用2克柳氮磺胺吡啶，持续6个月，另一组服用安慰剂。13名患者（6名服用安慰剂，7名服用柳氮磺胺吡啶）退出试验，被视为治疗失败。经过6个月的随访，服用柳氮磺胺吡啶的30名患者中有15名的疗效被评为良好或非常好，而服用安慰剂的30名患者中只有6名（p<0.02）。此外，服用柳氮磺胺吡啶的患者非甾体抗炎药的每日消耗量、功能指数和血浆IgG浓度均显著下降。这些数据表明，柳氮磺胺吡啶可能是强直性脊柱炎中脊柱炎的一种安全有效的治疗方法。
